To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.

8 hours ago

Journal

BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)

simvastatin • atorvastatin

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer (clinicaltrials.gov)

P2, N=36, Recruiting, Medical University of South Carolina | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

3 days ago

Trial completion date • Trial primary completion date

simvastatin

Paeonol alleviates atherosclerosis by inhibiting CD8+ T-cell activation via targeting the SYK/NFATc1 signaling pathway in ApoE-/- mice. (PubMed, J Ethnopharmacol)

SYK in CD8+ T-cells represents a potential therapeutic target for atherosclerosis. Pae inhibits atherosclerosis by blocking the SYK/NFATc1 pathway to reduce cytotoxic mediator release and prevent vascular endothelial cell injury.

3 days ago

Preclinical • Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • SYK (Spleen tyrosine kinase) • GZMB (Granzyme B) • APOE (Apolipoprotein E) • NFATC1 (Nuclear Factor Of Activated T Cells 1)

simvastatin

Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia (clinicaltrials.gov)

P=N/A, N=6927, Completed, JW Pharmaceutical

4 days ago

New trial

pitavastatin

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (clinicaltrials.gov)

P2, N=52, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

4 days ago

Trial completion date

simvastatin

The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. (PubMed, Ann N Y Acad Sci)

Furthermore, in vivo experiments indicate that PDAC tumors with high TRIB1 expression were more sensitive to the HMGCR inhibitor atorvastatin. Collectively, our findings highlight the critical role of the TRIB1-PPARγ-HMGCR axis in the metabolic rewiring of PDAC and suggest that TRIB1 may serve as a predictive biomarker for optimizing statin-based metabolic therapies.

4 days ago

Journal

PPARG (Peroxisome Proliferator Activated Receptor Gamma) • TRIB1 (Tribbles Pseudokinase 1)

atorvastatin

Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides (clinicaltrials.gov)

P4, N=88, Active, not recruiting, JW Pharmaceutical

5 days ago

New P4 trial

pitavastatin

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study (clinicaltrials.gov)

P1, N=15, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: May 2025 --> May 2027

8 days ago

Trial completion date • Trial primary completion date

10d

Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis (clinicaltrials.gov)

P2, N=50, Recruiting, CAMC Health System | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Jun 2026 --> Mar 2027

10 days ago

Enrollment open • Trial completion date • Trial primary completion date

atorvastatin

10d

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) (clinicaltrials.gov)

P1, N=39, Not yet recruiting, Merck Sharp & Dohme LLC

10 days ago

New P1 trial

11d

Transcriptional and Pathway Level Heterogeneity in Luminal A Breast Cancer: A Framework for Precision Therapy. (PubMed, Arch Med Res)

Our integrative multi-omics analysis reveals the complex molecular architecture of Luminal A breast cancer, characterized by transcriptional and pathway-level heterogeneity. The findings advocate for subtype-specific therapeutic interventions targeting transcription factor networks, redox balance, and the tumor microenvironment. This systems-level framework provides a foundation for precision risk stratification and treatment optimization in Luminal A breast cancer.

11 days ago

Journal

CEBPA (CCAAT Enhancer Binding Protein Alpha) • SOX2 • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PTTG1 (PTTG1 Regulator Of Sister Chromatid Separation, Securin) • TLX1 (T Cell Leukemia Homeobox 1)

HR positive

dexamethasone • simvastatin

12d

Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) (clinicaltrials.gov)

P2, N=154, Recruiting, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026

12 days ago

Enrollment open • Trial initiation date